The demand for Lipid-Lowering Agents in the United Arab Emirates has been on the rise in recent years.
Customer preferences: Patients in the United Arab Emirates are increasingly becoming health-conscious and are taking measures to prevent cardiovascular diseases. This has led to a rise in the demand for Lipid-Lowering Agents, which are used to manage cholesterol levels in the body. The population in the UAE is also becoming more aware of the benefits of preventative healthcare, which has led to an increase in demand for these drugs.
Trends in the market: The Lipid-Lowering Agents market in the United Arab Emirates is expected to grow due to the high prevalence of cardiovascular diseases in the country. The market is also witnessing an increase in the number of generic drugs, which are more affordable than branded drugs. The government is also taking measures to regulate drug prices, which has led to an increase in the affordability of these drugs.
Local special circumstances: The United Arab Emirates has a high prevalence of cardiovascular diseases, which has led to an increase in the demand for Lipid-Lowering Agents. The country has a high prevalence of risk factors such as obesity, diabetes, and hypertension. The government has taken measures to address these risk factors by promoting healthy lifestyles and increasing awareness about the importance of preventative healthcare.
Underlying macroeconomic factors: The United Arab Emirates has a growing population, which has led to an increase in the demand for healthcare services. The country has a well-developed healthcare system, which has led to an increase in the availability of Lipid-Lowering Agents. The government is also investing in the healthcare sector, which has led to an increase in the number of healthcare facilities in the country. The country's strong economy has also led to an increase in the affordability of these drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
